Hints and tips:
...Pharma on espionage charges....
...Astellas Pharma bought eye-treatment specialist Iveric Bio in a $5.9bn deal in May. Mizuho splashed out $550mn for US boutique investment bank Greenhill & Co....
...Astellas Pharma has agreed to buy US biotech group Iveric Bio for roughly $5.9bn, marking the Japanese drugmaker’s largest-ever acquisition and giving it access to the rapidly expanding market for age-related...
...It remained unclear whether the arrest was politically motivated or specific to Astellas....
...Pharma; levied a record fine against Deloitte, and amended its espionage law to cover ordinary business activities....
...In particular, WBA pointed to a 2.3 per cent year-on-year rise in sales at its main Retail Pharmacy USA division, with a rise in pharmacy sales offsetting declining retail sales....
...Our 10% WACC remains a premium to our mid-cap pharma peer average 8.6% which reflects our view of increased risk around single product execution....
...Campari will be hard hit by COVID-19 due to high On Trade exposure, especially in core markets of Italy and the USA....
...In September last year, Novartis said it would sell parts of the Sandoz US business to Aurobindo Pharma USA to focus on “higher growth areas”....
...On Thursday, Novartis said it would sell portions of the Sandoz US portfolio to Aurobindo Pharma USA in order to focus on “higher growth areas”....
...In April last year Fresenius, a large German medical products group, announced an acquisition of American generics pharma company Akorn for nearly $5bn....
...Astellas Pharma said in a statement: We deeply regret our failings, and in light of this we have reinforced our focus on patient safety....
...Japanese drugmaker Astellas Pharma has said it “deeply regrets” safety failings that on Friday triggered a threat of permanent expulsion from the UK’s pharmaceutical industry trade body....
...Pfizer generated $141m from sales of Xtandi in the US, which are shared with Japanese pharmaceutical group Astellas under a corporate alliance....
...The companies now under investigation are: Heritage Pharmaceuticals, Inc.; Aurobindo Pharma USA, Inc.; Citron Pharma, LLC; Mayne Pharma (USA), Inc.; Mylan Pharmaceuticals, Inc.; Teva Pharmaceuticals USA;...
...In 2010, Astellas Pharma went public with a $52 a share offer for OSI Pharmaceuticals and then nominated new directors. The two sides agreed a $57.50 offer....
...Pfizer recorded $141m of revenues from the medicine, which is sold under a revenue-sharing agreement with Japanese drugmaker Astellas Pharma — around a fifth lower than the $169m that Wall Street analysts...
...Japanese prescription drug maker Astellas Pharma, a company that derives a third of its revenue from North America, according to Bloomberg data, tumbled 3.9 per cent....
...Asian pharma groups were also under the cosh as they played catch-up to sector falls in the US and Europe....
.... ———- Chartwatch Drug donations Pharma companies provide more than 1.8bn treatments a year for neglected tropical diseases....
...Total revenues for Xtandi were already forecast to rise from $2.2bn in the last four quarters to over $5bn in 2020 (these are shared equally with Astellas Pharma)....
...In Japan, Takeda Pharmaceutical slid 2.7 per cent, Astellas Pharma fell 3.9 per cent and Shionogi sank 3.7 per cent on Thursday morning, while in Australia biotech company CSL Ltd dropped 1.4 per cent and...
...Such complaints are unlikely to subside now that Xtandi is owned by Pfizer, among the biggest pharma groups....
...The move quickly spurred market speculation that Mr Son would revive talks for a merger between SoftBank-owned Sprint and rival T-Mobile USA....
...Astellas to have a higher market cap.”...
International Edition